Louise Provencher

8.5k total citations · 3 hit papers
110 papers, 4.8k citations indexed

About

Louise Provencher is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Louise Provencher has authored 110 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 45 papers in Cancer Research and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Louise Provencher's work include Breast Cancer Treatment Studies (42 papers), HER2/EGFR in Cancer Research (36 papers) and Cancer Treatment and Pharmacology (32 papers). Louise Provencher is often cited by papers focused on Breast Cancer Treatment Studies (42 papers), HER2/EGFR in Cancer Research (36 papers) and Cancer Treatment and Pharmacology (32 papers). Louise Provencher collaborates with scholars based in Canada, United States and France. Louise Provencher's co-authors include Elizabeth Maunsell, Julie Lemieux, André Robidoux, Arlene Chan, Gilles Romieu, Xavier Pivot, Luc Dirix, Piotr Tomczak, Brigitte Poirier and Caroline Diorio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Louise Provencher

107 papers receiving 4.7k citations

Hit Papers

Phase III Study of Bevaci... 2010 2026 2015 2020 2010 2014 2014 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2010 700 citations Louise Provencher et al. Journal of Clinical Oncology profile →
  2. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
    2014 555 citations Brigitte Poirier, Louise Provencher et al. Journal of Clinical Oncology profile →
  3. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    2014 407 citations Kathleen I. Pritchard, Louise Provencher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Louise Provencher Canada 31 3.2k 1.8k 1.1k 842 803 110 4.8k
Shin‐Cheh Chen Taiwan 35 2.9k 0.9× 1.3k 0.7× 1.8k 1.6× 666 0.8× 700 0.9× 128 4.9k
Peter Barrett‐Lee United Kingdom 35 2.6k 0.8× 1.4k 0.7× 671 0.6× 885 1.1× 470 0.6× 121 5.0k
Gloria Broadwater United States 42 3.1k 1.0× 1.8k 1.0× 1.0k 0.9× 1.2k 1.4× 592 0.7× 182 6.2k
Sherko Kümmel Germany 37 2.5k 0.8× 2.0k 1.1× 814 0.7× 521 0.6× 910 1.1× 227 5.0k
Ingo Bauerfeind Germany 29 2.2k 0.7× 2.2k 1.2× 1.0k 0.9× 559 0.7× 1.1k 1.3× 103 4.4k
Giulia Bianchi Italy 32 4.8k 1.5× 2.2k 1.2× 1.6k 1.4× 1.0k 1.2× 450 0.6× 127 6.1k
Steven E. Come United States 44 3.9k 1.2× 2.6k 1.4× 1.5k 1.4× 742 0.9× 1.2k 1.5× 166 6.7k
Yazid Belkacémi France 34 1.3k 0.4× 1.4k 0.7× 870 0.8× 382 0.5× 1.1k 1.4× 212 4.1k
Karen Gelmon Canada 18 2.1k 0.6× 1.9k 1.1× 705 0.6× 673 0.8× 813 1.0× 29 4.2k
Seigo Nakamura Japan 34 2.3k 0.7× 1.7k 0.9× 753 0.7× 761 0.9× 833 1.0× 233 4.3k

Countries citing papers authored by Louise Provencher

Since Specialization
Citations

This map shows the geographic impact of Louise Provencher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise Provencher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise Provencher more than expected).

Fields of papers citing papers by Louise Provencher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louise Provencher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise Provencher. The network helps show where Louise Provencher may publish in the future.

Co-authorship network of co-authors of Louise Provencher

This figure shows the co-authorship network connecting the top 25 collaborators of Louise Provencher. A scholar is included among the top collaborators of Louise Provencher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louise Provencher. Louise Provencher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guillaumie, Laurence, Véronique Turcotte, Julie Lemieux, et al.. (2024). Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results. Journal of Cancer Survivorship. 19(6). 1846–1860.
2.
Cescon, David W., John Hilton, Serafín Morales, et al.. (2023). A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 30(2). 334–343. 10 indexed citations
3.
Geyer, Charles E., Hanna Bandos, Priya Rastogi, et al.. (2022). Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). Breast Cancer Research and Treatment. 193(3). 555–564. 4 indexed citations
4.
5.
Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations
6.
Poirier, Éric, Christine Desbiens, Brigitte Poirier, et al.. (2017). Characteristics and long‐term survival of patients diagnosed with pure tubular carcinoma of the breast. Journal of Surgical Oncology. 117(6). 1137–1143. 14 indexed citations
7.
Furrer, Daniela, Simon Jacob, Chantal Caron, et al.. (2017). Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer. Anticancer Research. 37(6). 3323–3329. 16 indexed citations
8.
Furrer, Daniela, et al.. (2016). Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer. Anticancer Research. 36(9). 4661–4666. 6 indexed citations
9.
Diorio, Caroline, Sophie Laberge, Chantal Caron, et al.. (2014). Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry in Breast Cancer. Applied immunohistochemistry & molecular morphology. 22(8). 613–618. 3 indexed citations
10.
Lemieux, Julie, Caroline Diorio, Marc‐André Côté, et al.. (2013). Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.. PubMed. 33(6). 2569–76. 59 indexed citations
11.
Deshaies, Isabelle, Louise Provencher, Simon Jacob, et al.. (2010). Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy. The Breast. 20(1). 50–55. 58 indexed citations
12.
Lavasani, Sayeh, John R. Mackey, Kathleen I. Pritchard, et al.. (2010). Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology. 17(4). 20–33. 23 indexed citations
13.
Al-Akoum, Mahéra, et al.. (2009). Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women. Menopause The Journal of The North American Menopause Society. 16(2). 307–314. 41 indexed citations
14.
Lauzier, Sophie, Elizabeth Maunsell, Myrto Mondor, et al.. (2009). Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Research and Treatment. 120(3). 685–691. 47 indexed citations
15.
Lemieux, Julie, Elizabeth Maunsell, & Louise Provencher. (2007). Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology. 17(4). 317–328. 268 indexed citations
16.
Samson, C., Paul Bessette, Jocelyne Chiquette, et al.. (2006). No Evidence of BRCA1/2 Genomic Rearrangements in High-Risk French-Canadian Breast/Ovarian Cancer Families. Genetic Testing. 10(2). 104–115. 41 indexed citations
17.
Rosen, Lee S., David Gordon, William Dugan, et al.. (2003). Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 100(1). 36–43. 243 indexed citations
18.
Provencher, Louise, et al.. (1999). Textes furtifs : Autour de la sculpture (1978-1999).
19.
Babul, Najib, Louise Provencher, Francis Laberge, Zoltan Harsanyi, & Dwight E. Moulin. (1998). Comparative Efficacy and Safety of Controlled‐Release Morphine Suppositories and Tablets in Cancer Pain. The Journal of Clinical Pharmacology. 38(1). 74–81. 46 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shin‐Cheh Chen Breakdown of academic impact, for papers by Peter Barrett‐Lee Breakdown of academic impact, for papers by Gloria Broadwater Breakdown of academic impact, for papers by Sherko Kümmel Breakdown of academic impact, for papers by Ingo Bauerfeind Breakdown of academic impact, for papers by Giulia Bianchi Breakdown of academic impact, for papers by Steven E. Come Breakdown of academic impact, for papers by Yazid Belkacémi Breakdown of academic impact, for papers by Karen Gelmon Breakdown of academic impact, for papers by Seigo Nakamura
Rankless by CCL
2026